Clinical Review | Published:

Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression

The American Journal of Gastroenterology volume 102, pages 20472056 (2007) | Download Citation

Subjects

Abstract

CONTEXT:

Proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) have become the mainstay of therapy in acid-related upper gastrointestinal disorders. There have been concerns raised about the possible association of PPIs with enteric infections.

OBJECTIVE:

 We conducted a systematic review to evaluate any association between acid suppression and enteric infection. We also assessed differences between types of enteric infections and the type of acid suppression.

DATA SOURCES:

Electronic searches of MEDLINE (1966–2005), EMBASE (1988–2005), and CINAHL (1982–2005) were undertaken using a combination of subject headings and text words related to PPI therapy, H2RAs, and enteric infections.

STUDY SELECTION:

All observational studies were eligible, including cross-sectional, case control, and cohort studies that evaluated risk of enteric infection associated with antisecretory therapy. Eligibility assessment was made by two independent researchers.

DATA EXTRACTION:

Information on study design, patient population, type of acid suppression, type of infection, and outcomes was collected. The odds ratio (OR) of taking acid suppression therapy in cases and controls was calculated and results were synthesized using a random effects model (DerSimonian and Laird, Stats direct version 2.4.4).

DATA SYNTHESIS:

A total of 12 papers evaluating 2,948 patients with Clostridium difficile were included in the review. There was an increased risk of taking antisecretory therapy in those infected with C. difficile (pooled OR 1.94, 95% CI 1.37–2.75). There was significant heterogeneity between the studies (P = 0.0006) that was not explained by planned subgroup analysis. The association was greater for PPI use (OR 1.96, 95% CI 1.28–3.00) compared with H2RA use (OR 1.40, 95% CI 0.85–2.29). A total of six studies evaluated Salmonella, Campylobacter, and other enteric infections in 11,280 patients. There was an increased risk of taking acid suppression in those with enteric infections (OR 2.55, 95% CI 1.53–4.26). There was significant heterogeneity between the studies (P < 0.0001) that was not explained by subgroup analysis. The association was greater for PPI use (OR 3.33, 95% CI 1.84–6.02) compared with H2RA use (OR 2.03, 95% CI 1.05–3.92).

CONCLUSION:

 There is an association between acid suppression and an increased risk of enteric infection. Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , . Gastro-oesophageal reflux disease. Lancet 2006;367:2086–2100.

  2. 2.

    , , , et al. Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults—update 2004. Can J Gastroenterol 2005;19:15–35.

  3. 3.

    , , , et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955–1960.

  4. 4.

    , , , et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies. CMAJ 2004;171:33–38.

  5. 5.

    , . Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: How much of a risk? Epidemiology 1997;8:571–574.

  6. 6.

    , , . Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: Influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology 1982;83:465–469.

  7. 7.

    , . Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.

  8. 8.

    , , , et al.Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.

  9. 9.

    , , , et al. Clostridium difficile-associated diarrhea and colitis in adults. Arch Intern Med 1986;146:95–100.

  10. 10.

    , , , et al.Gastric acid suppression does not promote clostridial diarrhoea in the elderly. Q J Med 2000;93:175–181.

  11. 11.

    , , , et al.Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243–245.

  12. 12.

    , , , et al.The impact of Clostridium difficile on a surgical service: A prospective study of 374 patients. Ann Surg 1998;227:296–301.

  13. 13.

    , , , et al. Drug risk factors associated with a sustained outbreak of Clostridium difficile diarrhea in a teaching hospital. Can J Infect Dis 1994;5:270–275.

  14. 14.

    , , , et al.Risk factors for the development of Clostridium difficile toxin-associated diarrhoea: A pilot study. Pharmacoepidemiol Drug Saf 2001;10:303–308.

  15. 15.

    , , , et al.Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001;22:572–575.

  16. 16.

    , , , et al.Omeprazole as a risk factor for Campylobacter gastroenteritis: Case-control study. BMJ 1996;312:414–415.

  17. 17.

    , , , et al.Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ 1994;308:176.

  18. 18.

    , , , et al.Salmonellosis in North Thames (East), UK: Associated risk factors. Epidemiol Infect 1999;122:201–207.

  19. 19.

    , . Diabetes mellitus, anti-secretory drugs and other risk factors for Campylobacter gastro-enteritis in adults: A case-control study. Epidemiol Infect 1997;119:307–311.

  20. 20.

    , , , et al.Increased incidence of bacterial diarrhoea in patients taking gastric acid antisecretory drugs. Eur J Gastroenterol Hepatol 1994;6:697–699.

  21. 21.

    , , , et al.Risk factors for Clostridium difficile stool cytotoxin b among critically ill patients: Role of sucralfate. J Infect Dis 1994;170:227–230.

  22. 22.

    , , , et al.Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990;11:283–290.

  23. 23.

    , , . Risk factors associated with Clostridium difficile diarrhea in hospitalized adult patients: A case-control study–sucralfate ingestion is not a negative risk factor. Infect Control Hosp Epidemiol 1996;17:232–235.

  24. 24.

    , , . Proton pump inhibitors: Are they a risk factor for Clostridium difficile diarrhea: A case-control study. Gastroenterol 2006; 20(Suppl A): 191.

  25. 25.

    , , , et al. Risk factors for Salmonella enteritidis and Typhimurium (DT104 and non-DT104) infections in the Netherlands: Predominant roles for raw eggs in enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect 2006;134:617–626.

  26. 26.

    , , , et al. Epidemic Clostridium difficile-associated diarrhea: Role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 1994;15:88–94.

  27. 27.

    , , , et al.Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated diarrhea. JAMA 2005;294:2989–2995.

  28. 28.

    , , , et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.

  29. 29.

    , , , et al.Clostridium difficile among hospitalized patients receiving antibiotics: A case-control study. Infect Control Hosp Epidemiol 2005;26:685–690.

  30. 30.

    , , , et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273–280.

  31. 31.

    , , , et al.Albumin, length of stay, and proton pump inhibitors: Key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005;6:105–108.

  32. 32.

    , , , et al.Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002;23:653–659.

  33. 33.

    , , . Infection due to Clostridium difficile among elderly residents of a long-term-care facility. Clin Infect Dis 1993;17:672–678.

  34. 34.

    , . Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171:51–58.

  35. 35.

    , , . Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887–1892.

  36. 36.

    . Meta-analysis: Can we mix apples and oranges? Am J Gastroenterol 2004;99:2297–2301.

  37. 37.

    , , . Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119–1129.

  38. 38.

    , , . American Gastroenterological Association Technical Review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756–1780.

  39. 39.

    , , , et al.The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol 2000;95:1448–1455.

  40. 40.

    , , , et al. The impact of illness in patients with moderate to severe gastro-esophageal reflux disease. BMC Gastroenterol 2005;5:23–30.

  41. 41.

    , , . Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med2003;139:843–857.

  42. 42.

    , , , et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;(4):CD002296.

Download references

Author information

Affiliations

  1. Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada

    • Jennifer Leonard
    • , John K Marshall
    •  & Paul Moayyedi

Authors

  1. Search for Jennifer Leonard in:

  2. Search for John K Marshall in:

  3. Search for Paul Moayyedi in:

Corresponding author

Correspondence to Paul Moayyedi.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1111/j.1572-0241.2007.01275.x

Further reading